Previous Article | Next Article ![]()
Journal of Virology, September 2000, p. 8349-8357, Vol. 74, No. 18
Departments of
Microbiology-Immunology1 and
Pathology,2 Interdepartmental
Immunobiology Center, Northwestern University Medical School, Chicago,
Illinois 60611, and The Ben May Institute for Cancer Research
and the Committee of Immunology, The University of Chicago, Chicago,
Illinois 606373
Received 1 March 2000/Accepted 20 June 2000
Theiler's murine encephalomyelitis virus (TMEV) is a natural mouse
pathogen which causes a lifelong persistent infection of the central
nervous system (CNS) accompanied by T-cell-mediated myelin destruction
leading to chronic, progressive hind limb paralysis. TMEV-induced
demyelinating disease (TMEV-IDD) is considered to be a highly relevant
animal model for the human autoimmune disease multiple sclerosis (MS),
which is thought to be initiated as a secondary consequence of a virus
infection. Although TMEV-IDD is initiated by virus-specific
CD4+ T cells targeting CNS-persistent virus,
CD4+ T-cell responses against self myelin protein epitopes
activated via epitope spreading contribute to chronic disease
pathogenesis. We thus examined the ability of antibodies directed
against B7 costimulatory molecules to regulate this chronic
virus-induced immunopathologic process. Contrary to previous studies
showing that blockade of B7-CD28 costimulatory interactions inhibit the initiation of experimental autoimmune encephalomyelitis, treatment of
SJL mice at the time of TMEV infection with murine CTLA-4
immunoglobulin or a combination of anti-B7-1 and anti-B7-2 antibodies
significantly enhanced clinical disease severity. Costimulatory
blockade inhibited early TMEV-specific T-cell and antibody responses
critical in clearing peripheral virus infection. The inhibition of
virus-specific immune responses led to significantly increased CNS
viral titers resulting in increased damage to myelin-producing
oligodendrocytes. Following clearance of the costimulatory antagonists,
epitope spreading to myelin epitopes was accelerated as a result of the increased availability of myelin epitopes leading to a more severe chronic disease course. Our results raise concern about the potential use of B7-CD28 costimulatory blockade to treat human autoimmune diseases potentially associated with acute or persistent virus infections.
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
CD28 Costimulatory Blockade Exacerbates Disease
Severity and Accelerates Epitope Spreading in a Virus-Induced
Autoimmune Disease
*
Corresponding author. Mailing address: Department of
Microbiology-Immunology, Northwestern University Medical School, 303 E. Chicago Ave., Chicago, IL 60611. Phone: (312) 503-7674. Fax: (312)
503-1154. E-mail: s-d-miller{at}nwu.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»